ARA-290 (Cibinetide): EPO-Derived Tissue Protection Peptide Research Overview

Erythropoietin (EPO) is a 165-amino acid glycoprotein cytokine that stimulates red blood cell production via the homodimeric EPO receptor (EPOR). However, EPO has also been shown to exert tissue-protective effects in many preclinical models, effects mediated by a different receptor complex consisting of EPOR plus the common beta receptor (βcR or CD131).^[1]

ARA-290 was developed by Brines, Cerami and colleagues by identifying the helix B surface of EPO as the region responsible for engaging the tissue-protective receptor while not engaging the classical EPOR homodimer. The 11-amino acid peptide captures this binding surface in a much smaller molecule.^[2]

ARA-290 is studied as a research reference compound that selectively activates the tissue-protective receptor without erythropoietic effects. It has not been approved by the FDA for any human therapeutic or medical purpose.

ARA-290 structural features:

• Length: 11 amino acids

• Source: mimics the surface of erythropoietin's helix B

• Form: linear synthetic peptide

• Molecular weight: approximately 1,200 Da

Native EPO engages two distinct receptor systems with different domains. The EPOR homodimer (driving erythropoiesis) requires the full three-dimensional context of EPO. The tissue-protective receptor (EPOR-βcR heterodimer) recognizes a specific surface presented by helix B. ARA-290 captures only this latter surface, making it a non-erythropoietic mimetic.^[2]

This selective activity was demonstrated in classical EPO bioassays. ARA-290 does not stimulate erythroid colony formation, distinguishing it pharmacologically from native EPO despite the structural similarity.

ARA-290 selectively engages the tissue-protective receptor complex.

The tissue-protective receptor consists of one EPOR subunit plus one common beta receptor (βcR, also called CD131) subunit. This heterodimeric complex is expressed on cells that experience tissue stress, neurons, cardiomyocytes, vascular endothelium, immune cells, but is not present on erythroid precursors.^[3]

Receptor activation produces JAK2-mediated phosphorylation and downstream PI3K/Akt and STAT3 signaling. In cells, the net effect in preclinical studies has been characterized as anti-apoptotic, anti-inflammatory, and supportive of tissue function under stress conditions.^[4]

ARA-290 research has spanned multiple preclinical injury and disease models.

Animal models of neuropathic pain have examined ARA-290 effects on mechanical and thermal sensitivity endpoints. The compound's neuroprotective receptor activity is the basis for these research lines.^[5]

Rodent cardiac ischemia-reperfusion models have included ARA-290 in experimental arms examining infarct size and cardiac function markers.^[4]

Preclinical and exploratory research has examined ARA-290 in inflammatory disease models including sarcoidosis-related small fiber neuropathy preparations.^[6]

ARA-290 is a small linear peptide with standard stability characteristics.

Lyophilized material is stored at minus 20 degrees Celsius.

Bacteriostatic water is the standard reconstitution solvent.

HPLC for purity, mass spectrometry for identity confirmation, and endotoxin screening. Each batch of Instant Peptides ARA-290 ships with a full Certificate of Analysis.

Instant Peptides supplies ARA-290 as a synthetic lyophilized reference compound. Material is supplied to qualified research professionals. Not for human or animal consumption.

View the product page for current pricing and the Certificate of Analysis for the active batch.